biostudies-literatureUnknown5Antonuzzo L<h4>Background</h4>Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelumab 1L maintenance in an Italian compassionate use program (CUP).<h4>Patients and methods</h4>In this prospective, noninterventional CUP, avelumab was provided on physician's request to patients with la/mUC without disease progression following four to six cycles of 1L PBC, after approval by the local ethics committees, per Italian compassionate use regulations.<h4>Results</h4>Between January 2021 and March 2022, 414 patients received avelumab 1L maintenance and were assessable for survivESMO real world data and digital oncology100068https://www.ebi.ac.uk/biostudies/studies/S-EPMC12836724biostudies-literatureREADY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma.PMC12836724Maruzzo MVenturini FAntonuzzo LSantini DIacovelli RBracarda SCalabro FFornarini GCerbone LDe Giorgi UCullura DMessina CColasanto RTambaro RCarrozza FDi Lorenzo GButi SNecchi AFazzi GfalseREADY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma.<h4>Background</h4>Avelumab first-line (1L) maintenance is recommended as the standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) without disease progression following 1L platinum-based chemotherapy (PBC). We report results from READY, a real-world study of avelumab 1L maintenance in an Italian compassionate use program (CUP).<h4>Patients and methods</h4>In this prospective, noninterventional CUP, avelumab was provided on physician's request to patients with la/mUC without disease progression following four to six cycles of 1L PBC, after approval by the local ethics committees, per Italian compassionate use regulations.<h4>Results</h4>Between January 2021 and March 2022, 414 patients received avelumab 1L maintenance and were assessable for surviv2024-01-01T00:00:00Z2024 Sep2026-07-15T06:19:03.88Z2026-06-30T03:23:08.37ZS-EPMC128367244164864610.1016/j.esmorw.2024.100068